Jazz pharmaceuticals plc (JAZZ)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Total revenues

2,161,761

1,890,922

1,618,693

1,487,973

1,324,803

1,172,875

872,423

585,979

272,277

173,781

128,449

Operating expenses:
Cost of product sales (excluding amortization of acquired developed technologies)

127,930

121,544

110,188

105,386

102,526

117,418

102,146

78,425

13,942

13,559

9,638

Selling, general and administrative

736,942

683,530

544,156

502,892

449,119

406,114

304,303

223,882

108,936

68,996

58,652

Research and development

299,726

226,616

198,442

162,297

135,253

85,181

41,632

20,477

14,120

25,612

36,561

Intangible asset amortization

354,814

201,498

152,065

101,994

98,162

126,584

79,042

65,351

7,448

7,825

7,668

Acquired in-process research and development

109,975

0

85,000

23,750

0

202,626

4,988

0

-

-

-

Impairment charge

0

42,896

0

0

31,523

39,365

0

0

-

-

-

Total operating expenses

1,629,387

1,276,084

1,089,851

896,319

816,583

977,288

532,111

388,135

144,446

115,992

112,519

Income (loss) from operations

532,374

614,838

528,842

591,654

508,220

195,587

340,312

197,844

127,831

57,789

15,930

Interest expense, net

-72,261

-77,075

-77,756

-61,942

-56,917

-52,713

-26,916

-16,869

-1,600

-12,724

22,796

Foreign exchange loss

-5,811

-6,875

-9,969

3,372

1,445

8,683

-1,697

-3,620

0

0

-

Gain (Loss) on Extinguishment and Modification of Debt

0

-1,425

0

-638

-16,815

0

-3,749

0

-1,247

-12,287

-

Income (loss) before income tax provision (benefit) and equity in loss (gain) of investees

454,302

529,463

441,117

532,446

435,933

151,557

307,950

177,355

124,984

32,778

-

Interest income and other, net

-

-

-

-

-

-

-

-

-

-

30

Income tax provision (benefit)

-73,200

80,200

-47,700

135,236

106,399

94,231

91,638

-83,794

0

0

-

Equity in loss (gain) of investees

-4,089

-2,203

-1,009

-379

0

0

-

-

-

-

-

Income from continuing operations

-

-

-

-

-

-

-

261,149

124,984

32,778

-

Income from discontinued operations, net of taxes

-

-

-

-

-

-

-

27,437

0

0

-

Net income

-

-

-

-

329,534

57,326

216,312

288,586

-

-

-

Net loss attributable to noncontrolling interests

-

-

-

-

-1

-1,061

0

0

-

-

-

Net Income (Loss) Attributable to Parent

523,367

447,098

487,848

396,831

329,535

58,387

216,312

288,586

124,984

32,778

-6,836

Net income (loss) per ordinary share:
Basic:
Income from continuing operations (in dollars per share)

-

-

-

-

-

-

-

4.61

3.01

0.90

-

Income from discontinued operations (in dollars per share)

-

-

-

-

-

-

-

0.48

0.00

0.00

-

Basic (in dollars per share)

9.22

7.45

8.13

6.56

5.38

0.98

3.71

5.09

3.01

0.90

-0.23

Diluted:
Income from continuing operations (in dollars per share)

-

-

-

-

-

-

-

4.34

2.67

0.83

-

Income from discontinued operations (in dollars per share)

-

-

-

-

-

-

-

0.45

0.00

0.00

-

Diluted (in dollars per share)

9.09

7.30

7.96

6.41

5.23

0.93

3.51

4.79

2.67

0.83

-0.23

Weighted-average ordinary shares used in per share calculations - basic (in shares)

56,749

59,976

60,018

60,500

61,232

59,746

58,298

56,643

41,499

36,343

30,018

Weighted-average ordinary shares used in per share calculations - diluted (in shares)

57,550

61,221

61,317

61,870

63,036

62,614

61,569

60,195

46,798

39,411

30,018

Product sales, net
Total revenues

2,135,601

1,869,473

1,601,399

1,477,261

1,316,819

1,162,716

865,398

580,527

266,518

170,006

115,108

Royalties and contract revenues
Total revenues

26,160

21,449

17,294

10,712

7,984

10,159

7,025

5,452

5,759

3,775

13,341